API Probiotics Strain
[INQ. NO. 2309C28] The Active Pharmaceutical Ingredient (API) Probiotics Strain, Lactobacillus acidophilus CKDB018, is unique in its class. It is the only strain registered as a raw material drug with Republic of Korea’s Ministry of Food and Drug Safety. The company plans to register an additional four strains, expanding its portfolio in this specialized sector.

Functional Probiotics Strain
CKD Bio Corp’s functional strains are produced in Republic of Korea’s only pharmaceutical GMP facility, ensuring the highest quality. These strains are categorized into two types: Clinical Functional Strains and Patented Functional Strains.

The former includes strains clinically proven to reduce neutral fats, alleviate symptoms of atopic dermatitis, and improve obesity. The latter consists of strains developed in-house, each with its registered patent for specific functionalities.

CKD Bio Corp is more than just a probiotics manufacturer; it’s a full-service Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO). Equipped with a dedicated GMP facility, the company can develop strains with new functionalities as per customer specifications.

The company also holds patented technologies like Airblock, which minimizes oxygen exposure for anaerobic strains, and Proline Feeding & Silk Fibroin Coating, aimed at enhancing the survival and adhesion of probiotics in the gut. These technologies are part of the company’s ongoing R&D to improve strain stability.

Founded in 2001 as a spin-off from CKD, CKD Bio Corp has leveraged its 50 years of fermentation technology expertise to become a global pharmaceutical company. With an Intestinal Microbiome Bank housing over 3,000 strains, the company is at the forefront of probiotics research and development.

Korean-Products.com | Blog Magazine of Korean products, brands and Goods